

UNIVERSITY TEKNOLOGI MARA

**INVESTIGATION OF *IN VITRO* METABOLISM OF
CARBAMAZEPINE USING CYP2C9 ENZYMES THROUGH
¹H-NMR SPECTROSCOPIC METHOD**

RAUDHATUN SA'ADIAH ITHNIN

**Dissertation submitted in partial fulfillment of the requirements for the
degree of Bachelor of Pharmacy (Hons)**

Faculty of Pharmacy

November 2008

ACKNOWLEDGEMENTS

Any large endeavor of this type cannot be completed without the help of many individuals. I am deeply indebted to many who rose the occasion and provided extra time, at short notice, to help in the completion of this project. In this regard I am particularly thankful to Dr Syed Adnan Ali Shah for his kindness, supervision, guidance and especially for his comments and suggestions throughout this project.

Special thanks to Prof. Ass. Dr. Teh Ley Kek, Mr. Tommy Julianto and Mr Lee Wee Leng who assisted my friends and me, who made sure that everyone did his or her job and remained on tract. Their supervisory and editorial task drove us to be more dedicated throughout the completion of this project.

I am also extremely grateful to many of the staff s of Pharmacogenomic and Institute of Chemistry and Herbal Remedies (iKUS) laboratory for providing me with the beneficial knowledge about the equipments in the laboratory and the exact way to use the equipments.

And finally, ventures such as this exact a heavy toll from the families of mine. I thank them for their tolerance of my absences, physically and emotionally. I am blessed and strengthened by their unconditional support and love, and for their sharing with us the belief that my efforts are worthwhile and useful.

TABLE OF CONTENTS

| | Page |
|--|---------|
| APPROVAL FORM | |
| TITLE PAGE | i |
| ACKNOLEGEMENT | ii |
| TABLE OF CONTENTS | iii |
| LIST OF TABLES | iv |
| LIST OF FIGURES | v |
| LIST OF SHCEMES | vi |
| LIST OF ABBREVIATIONS | vii |
| ABSTRACT | ix |
| | |
| CHAPTER ONE (INTRODUCTION) | 1 - 2 |
| | |
| CHAPTER TWO (LITERATURE REVIEW) | |
| 2.1. Description of Carbamazepine. | 3 - 4 |
| 2.2. Description of Cytochrome 2C9 (Pharmacogenomic variations) and enzymatic reaction with Carbamazepine. | 5 - 7 |
| 2.3. Metabolism of Carbamazepine. | 7 - 10 |
| 2.4. NMR Spectoscopic Methods. | 11 |
| | |
| CHAPTER THREE (MATERIAL AND METHODS) | |
| 3.1. Experimental. | 12 |
| 3.1.1. General Experimental Conditions. | |
| 3.1.1.1. General Notes. | 12 |
| 3.1.1.2. Instrumentations. | 12 |
| 3.1.1.3. Chromatographic Analysis. | 12 |
| 3.1.1.4. General Enzymatic reaction and Extraction Procedure. | 13 |
| 3.1.2. Isolation of Carbamazepine (1) from the drug. | 13 |
| 3.1.3. Material. | 14 |
| 3.1.4. <i>In vitro</i> incubation system for Carbamazepine metabolism. | 14 - 15 |
| 3.1.5. Preparation of pure extract of metabolites. | 15 |
| | |
| 3.2. Analysis | |
| 3.2.1. Chromatographic Technique. | 16 - 17 |
| 3.2.2. Characterization of metabolites. | 18 - 19 |

ABSTRACT

The main objective of this *in vitro* study were plan to identify major Carbamazepine metabolites formed in association with CYP2C9 enzymes respectively using variable such as different concentration of Carbamazepine, pH of medium and concentration of CYP2C9 enzymes. Other goals were to identify the structural changes during metabolism of Carbamazepine compound. There are several techniques involved in order to achieve the goals of this project. The first process involves enzymatic reactions of Carbamazepine. The reaction samples were subjected to extract and evaporate to get pure extract. Obtained extract were further subjected to Thin Layer Chromatographic (TLC) techniques in order to identify transformed metabolites. The suspected metabolites detected on TLC plates were sent for characterization as long as identification using ¹H-NMR spectrometer. Two compounds were detected namely, compound (2) and (3) respective to pH 5.8 and 7.4. Concisely, even though the compounds are not main metabolites in metabolism of Carbamazepine as stated in various literatures, we managed to identify new potential compounds that may have possible contribution in various toxicity problem of Carbamazepine.

CHAPTER 1

INTRODUCTION

Carbamazepine is now an established antiepileptic drug which classified under iminostilbene group. Nowadays Carbamazepine to be known first – line drug of choice in most types of epilepsy. However, it associated with variety of idiosyncratic adverse effects due to the formation of chemically reactive metabolite formed in the body. Thus, it may cause cardiovascular, dermatologic, immunologic and hematologic malfunction.

Cytochrome P450 enzymes found largely in liver are involved in the metabolism of most drugs include Carbamazepine. CYP2C9 enzymes belong to CYP450 subfamily which involved in mostly clinically important drug interaction. Genetic variation in CYP2C9 may either cause increase or decrease the interaction intensity of medications. During the research we would concentrate on CYP2C9 enzymatic reaction with Carbamazepine. Carbamazepine is demonstrated as mild inducer for CYP2C9 and this may reduce the efficiency of most of CYP2C9 substrate.

Few researches were published regarding the involvement of CYP2C9 enzymes responsible for formation of reactive Carbamazepine metabolites. The metabolites that may be formed from CYP2C9 enzymatic reactions may also associated with toxicity effects of Carbamazepine.